Synthesis, redox properties, in vivo formation, and neurobehavioral effects of N-acetylcysteinyl conjugates of dopamine: Possible metabolites of relevance to Parkinson's disease

Chemical Research in Toxicology

Volumn 9, Issue 7, 1996, Pages 1117-1126

  Shen, Xue Ming ^a   Xia, Bing ^a   Wrona, Monika Z ^a   Dryhurst, Glenn ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CYSTEINE CONJUGATE; DOPAMINE; GAMMA GLUTAMYLTRANSFERASE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONJUGATION; CONTROLLED STUDY; CYCLIC POTENTIOMETRY; HYPERACTIVITY; MALE; MESENCEPHALON; MOUSE; NEUROTOXICITY; NONHUMAN; OXIDATION REDUCTION REACTION; PARKINSON DISEASE;

ACETYLCYSTEINE; ANIMALS; BRAIN; CYSTEINYLDOPA; DISEASE MODELS, ANIMAL; DOPAMINE; MALE; MICE; MICE, INBRED ICR; OXIDATION-REDUCTION; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; PARKINSONIA;

EID: 0029967920     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx960052v     Document Type: Article

References (36)

1. Hornykiewicz, O., and Kish, S. J. (1986) Biochemical pathophysiology of Parkinson's Disease. Adv. Neurol. 45, 19-34.
2. Hornykiewicz, O. (1989) Aging and neurotoxins as causitive factors in idiopathic Parkinson's Disease: A critical analysisd of neurochemical evidence. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 13, 319-328.
3. Dexter, D. T., Carter, C. J., Wells, F. R., Javoy-Agid, F., Lees, A. J., Jenner, P., and Marsden, C. D. (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's Disease. J. Neurochem. 52, 381-389.
4. Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., and Marsden, C. D. (1990) Mitochondrial complex I deficiency in Parkinson's Disease. J. Neurochem. 54, 323-327.
5. Riederer, P., Sofic, E., Rausch, W. D., Schmidt, B., Reynolds, G., Jellinger, K., and Youdim, M. B. H. (1989) Transition metals, ferritin, glutathione and ascorbic acid in Parkinsonian brain. J. Neurochem. 52, 515-520.
6. Jenner, P. (1993) Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol. Scand. 87 (Suppl. 146), 6-13.
7. Fornstedt, B., Brun, A., Rosengren, E., and Carlsson, A. (1989) The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra. J. Neural Transm.: Parkinson's Dis. Dementia Sect. 1, 279-295.
8. Sian, J., Dexter, D. T., Jenner, P., and Marsden, C. D. (1992) Glutathione-related enzymes in brain in basal ganglia degenerative disorders. Br. J. Pharmacol. 107 (Suppl.), 428P.
9. Mann, D. M. A., and Yates, P. O. (1983) Possible role of neuromelanin in the pathogenesis of Parkinson's disease. Mech. Ageing Dev. 21, 193-203.
10. Hirsch, E. C., Graybiel, A. M., and Agid, Y. (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334, 345-348.
11. Kastner, A., Hirsch, E. C., Lejeune, O., Javoy-Agid, F., Rascol, O., and Agid, Y. (1992) Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J. Neurochem. 59, 1080-1089.
12. Hirsch, E. C. (1992) Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson's disease? Ann. Neurol. 32, S88-S93.
13. Graham, D. G. (1978) Oxidation pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14, 633-643.
14. Zhang, F., and Dryhurst, G. (1995) Influence of glutathione on the oxidation chemistry of the catecholaminergic neurotransmitter dopamine. J. Electroanal. Chem. Interfacial Electrochem. 398, 117-128.
15. Zhang, F., and Dryhurst, G. (1994) Effects of L-cysteine on the oxidation chemistry of dopamine: New reaction pathways of potential relevance to idiopathic Parkinson's Disease. J. Med. Chem. 37, 1084-1098.
16. Carstam, R., Brinck, C., Hindemith-Angustsson, A., Rorsman, H., and Rosengren, E. (1991) The neuromelanin of the substantia nigra. Biochim. Biophys. Acta 1097, 152-160.
17. Slivka, A., Mytilineou, C., and Cohen, G. (1987) Histochemical evaluation of glutathione in brain. Brain Res. 409, 275-284.
18. Shen, X.-M., and Dryhurst, G. (1996) Further insights into the influence of L-cysteine on the oxidation chemistry of dopamine: Reaction pathways of potential relevance to Parkinson's Disease. Chem. Res. Toxicol. 9, 751-763.
19. Steventon, G. B., Heafield, M. T. E., Waring, R. H., and Williams, A. C. (1989) Xenobiotic metabolism in Parkinson's Disease. Neurology 39, 883-887.
20. Waring, R. H., Sturman, S. G., Smith, M. C. G., Steventon, G. B., Heafield, M. T. E., and Williams, A. C. (1989) S-Methylation in motoneuron and Parkinson's Disease. Lancet, 356-357.
21. Yong, V. W., Perry, T. L., and Krisman, A. A. (1985) Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant treatment. Neurosci. Lett. 63, 56-60.
22. Raps, S. P., Lai, J. C. K., Hertz, L., and Cooper, A. J. L. (1989) Glutathione is present in high concentrations in cultured astrocytes but not in cultured neurons. Brain Res. 493, 398-401.
23. Sagara, J.-I., Miura, K., and Bannai, S. (1993) Maintenance of neuronal glutathione by glial cells. J. Neurochem. 61, 1672-1676.
24. Liccione, J. L., and Maines, M. D. (1988) Selective vulnerability of glutathione metabolism and cellular defense mechanisms in rat striatum to manganese. J. Pharmacol. Exp. Ther. 247, 156-161.
25. Orlowski, M., and Meister, A. (1979) The γ-glutamyl cycle. A possible transport system for amino acids. Proc. Nat. Acad. Sci. U.S.A. 67, 1248-1255.
26. Meister, A. (1974) Glutathione metabolism and function via the γ-glutamyl cycle. Life Sci. 15, 177-190.
27. Hiramatsu, M., Kumagai, Y., Unger, S. E., and Cho, A. K. (1990) Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J. Pharmacol. Exp. Ther. 254, 521-527.
28. Patel, N., Kumagai, Y., Unger, S. E., and Cho, A. K. (1991) Transformation of dopamine and α-methyldopamine by NG-108-15 cells: Formation of thiol adducts. Chem. Res. Toxicol. 4, 421-426.
29. Miller, R. T., Lau, S. S., and Monks, T. J. (1995) Metabolism of 5-(glutathion-S-yl)-α-methyldiopamine following intracerebroventricular administration to male Sprague-Dawley rats. Chem. Res. Toxicol. 8, 634-641.
30. Zhang, F., and Dryhurst, G. (1995) Reactions of cysteine and cysteinyl derivatives with dopamine-o-quinone and further insights into the oxidation chemistry of 5-S-cysteinyldopamine: Potential relevance to idiopathic Parkinson's Disease. Bioorg. Chem. 23, 193-216.
31. Wrona, M. Z., Goyal, R. N., Turk, D., Blank, C. L., and Dryhurst, G. (1992) 5,5′-Dihydroxy-4,4′-bitryptamine: A potentially aberrant neurotoxic metabolite of serotonin. J. Neurochem. 59, 1392-1398.
32. Tse, D. C. S., McCreery, R. L., and Adams, R. N. (1976) Potential oxidative pathways of brain catecholamines. J. Med. Chem. 19, 37-40.
33. Zhang, F., and Dryhurst, G. (1993) Oxidation chemistry of dopamine: Possible insights into the age-dependent loss of dopaminergic nigrostriatal neurons. Bioorg. Chem. 21, 392-410.
34. Dixon, W. J. (1965) The up-and-down method for small samples. J. Am. Stat. Assoc. 60, 967-978.
35. Cheng, F.-C., Kuo, J.-S., Ghia, L.-G., and Dryhurst, G. (1996) Elevated 5-S-Cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: Possible markers for and potential insights into the pathoetiology of Parkinson's disease. J. Neural Transm. 103, 433-446.
36. Jenner, P., Dexter, D. T., Sian, J., Schapira, A. H. V., and Marsden, D. (1992) Oxidative stress as a cause of nigral cell death in Parkinson's Disease and Incidental Lewy Body Disease. Ann. Neural. 32 (Suppl.), S82-S87.